Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From the ACT Autopsy Cohort.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
26 Nov 2024
26 Nov 2024
Historique:
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
31
10
2024
Statut:
ppublish
Résumé
Cerebral amyloid angiopathy (CAA) is common in older adults and is associated with dementia. Less is known whether this association is mediated by Alzheimer disease (AD) neuropathologic changes, the examination of which was the objective of this study. This was a retrospective cross-sectional examination of the Kaiser Permanente Washington database of the Adult Changes in Thought (ACT) autopsy cohort with information on CAA, dementia, the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (amyloid neuritic plaques), and Braak (tau neurofibrillary tangles). CAA was diagnosed by immunohistochemistry and dementia by ACT Consensus Diagnostic Conference. AD neuropathology was categorized by CERAD scores and Braak stages. Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% CIs of the associations of CAA with dementia, adjusting for age at death and sex, and with additional adjustments separately for CERAD scores (moderate-severe vs mild-absent), Braak stages (V-VI vs 0-IV), The 848 participants had a mean age of 86.7 ± 4.6 years at death, and 57.6% were female. CAA was present in 322 participants (38.0%), of whom 152, 145, and 25 had mild, moderate, and severe CAA, respectively. Dementia was present in 384 participants (45.3%), of whom 317 had AD. Dementia was more common in those with CAA than without (53.7% vs 40.1%; age-sex-adjusted OR 1.57, 95% CI 1.18-2.10). This association remained significant after separate adjustment for other covariates but lost significance when adjusted for CERAD scores (OR 1.27, 95% CI 0.93-1.71) and Braak stages (OR 0.96, 95% CI 0.69-1.33). Findings from our formal mediation analyses show that ORs (95% CIs) for NIE of CERAD scores and Braak stages were 1.25 (1.13-1.37) and 1.63 (1.38-1.88), respectively, and CERAD scores and Braak stages mediated 53% and 111% of the total association, respectively. We observed a significant association between CAA and dementia that disappeared when adjusted for CERAD or Braak stages. Findings from our mediation analyses suggest that the CAA-dementia association may be potentially mediated by AD neuropathologic changes. This hypothesis needs to be tested in future mechanistic studies in AD accounting for unmeasured confounders.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Cerebral amyloid angiopathy (CAA) is common in older adults and is associated with dementia. Less is known whether this association is mediated by Alzheimer disease (AD) neuropathologic changes, the examination of which was the objective of this study.
METHODS
METHODS
This was a retrospective cross-sectional examination of the Kaiser Permanente Washington database of the Adult Changes in Thought (ACT) autopsy cohort with information on CAA, dementia, the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (amyloid neuritic plaques), and Braak (tau neurofibrillary tangles). CAA was diagnosed by immunohistochemistry and dementia by ACT Consensus Diagnostic Conference. AD neuropathology was categorized by CERAD scores and Braak stages. Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% CIs of the associations of CAA with dementia, adjusting for age at death and sex, and with additional adjustments separately for CERAD scores (moderate-severe vs mild-absent), Braak stages (V-VI vs 0-IV),
RESULTS
RESULTS
The 848 participants had a mean age of 86.7 ± 4.6 years at death, and 57.6% were female. CAA was present in 322 participants (38.0%), of whom 152, 145, and 25 had mild, moderate, and severe CAA, respectively. Dementia was present in 384 participants (45.3%), of whom 317 had AD. Dementia was more common in those with CAA than without (53.7% vs 40.1%; age-sex-adjusted OR 1.57, 95% CI 1.18-2.10). This association remained significant after separate adjustment for other covariates but lost significance when adjusted for CERAD scores (OR 1.27, 95% CI 0.93-1.71) and Braak stages (OR 0.96, 95% CI 0.69-1.33). Findings from our formal mediation analyses show that ORs (95% CIs) for NIE of CERAD scores and Braak stages were 1.25 (1.13-1.37) and 1.63 (1.38-1.88), respectively, and CERAD scores and Braak stages mediated 53% and 111% of the total association, respectively.
DISCUSSION
CONCLUSIONS
We observed a significant association between CAA and dementia that disappeared when adjusted for CERAD or Braak stages. Findings from our mediation analyses suggest that the CAA-dementia association may be potentially mediated by AD neuropathologic changes. This hypothesis needs to be tested in future mechanistic studies in AD accounting for unmeasured confounders.
Identifiants
pubmed: 39481068
doi: 10.1212/WNL.0000000000210009
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e210009Références
Stroke. 1996 Aug;27(8):1333-7
pubmed: 8711797
Ann Neurol. 1991 Nov;30(5):637-49
pubmed: 1763890
Nat Protoc. 2006;1(3):1591-5
pubmed: 17406451
Stroke. 2018 Feb;49(2):491-497
pubmed: 29335334
Ann Neurol. 2011 Feb;69(2):320-7
pubmed: 21387377
J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):982-994
pubmed: 28844070
J Alzheimers Dis. 2017;59(4):1307-1315
pubmed: 28731431
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
CNS Neurosci Ther. 2011 Oct;17(5):514-24
pubmed: 20553310
Alzheimers Res Ther. 2015 Feb 27;7(1):21
pubmed: 25722748
Neurology. 2011 Apr 26;76(17):1485-91
pubmed: 21490316
Neurobiol Aging. 2015 Oct;36(10):2702-8
pubmed: 26239176
Neurodegener Dis. 2016;16(3-4):218-24
pubmed: 26756746
Am J Pathol. 1996 Jun;148(6):2083-95
pubmed: 8669492
J Neuropathol Exp Neurol. 2013 Jul;72(7):708-15
pubmed: 23771217
J Lipid Res. 1990 Mar;31(3):545-8
pubmed: 2341813
PLoS One. 2017 Jul 10;12(7):e0180923
pubmed: 28700676
Neurology. 1991 Apr;41(4):479-86
pubmed: 2011243
Neurology. 2015 Mar 24;84(12):1206-12
pubmed: 25716356
Genomics. 1988 Nov;3(4):373-9
pubmed: 3243553
Int Psychogeriatr. 1994 Spring;6(1):45-58; discussion 62
pubmed: 8054493
Neurology. 2002 Jun 11;58(11):1629-34
pubmed: 12058090
Ann Intern Med. 2006 Jan 17;144(2):73-81
pubmed: 16418406
JAMA Neurol. 2022 Jan 1;79(1):13-21
pubmed: 34807243
Int J Mol Sci. 2023 Jan 01;24(1):
pubmed: 36614219
Neurology. 2015 Dec 1;85(22):1930-6
pubmed: 26537052
Mol Neurodegener. 2022 Nov 8;17(1):72
pubmed: 36348357
Ann Neurol. 2001 Jun;49(6):697-705
pubmed: 11409420
Age Ageing. 1996 Mar;25(2):125-9
pubmed: 8677826
JAMA Neurol. 2014 Nov;71(11):1394-404
pubmed: 25199842
Brain. 2022 Aug 27;145(8):2823-2833
pubmed: 35759327
Int J Mol Sci. 2019 Dec 14;20(24):
pubmed: 31847365
J Alzheimers Dis. 2020;74(1):189-197
pubmed: 31985469
BMC Med. 2019 Mar 20;17(1):64
pubmed: 30890171
Neurology. 1996 Jul;47(1):190-6
pubmed: 8710076
Arch Neurol. 2002 Nov;59(11):1737-46
pubmed: 12433261
Psychopharmacol Bull. 1988;24(4):705-8
pubmed: 3249772
Neurobiol Aging. 2015 Nov;36(11):2946-2953
pubmed: 26341746
Br J Psychiatry. 1968 Jul;114(512):797-811
pubmed: 5662937
J Alzheimers Dis. 2018;63(2):821-833
pubmed: 29689717
Stroke. 2012 Jun;43(6):1675-7
pubmed: 22535269
JAMA. 2021 Sep 21;326(11):1045-1056
pubmed: 34546296